Hy BioPharma Inc, a biopharmaceutical company founded in 2006, is developing and commercializing Hypericin, an innovative drug technology effective in the treatment of cancer, autoimmune disorders, and inflammation.
Hy BioPharma’s vision is to bring this advanced technology rapidly to market with new drug applications (NDAs) with two FDA-approved Orphan indications.
In June 2008, Hy BioPharma entered Phase III clinical development for Topical Phototherapy of Skin Lymphoma
 |
|
The red elevations
indicate the areas with the highest concentration
of the drug which is in the "Golgi apparatus"
in the vicinity of the cell nucleus. |
Hypericin is the culmination of more than 15 years of research and development carried out in conjunction with scientists at New York University and the Weizmann Institute.
|
|
|
|
|
Oncology: The FDA has approved
Orphan Drug status for Hypericin to treat two
forms of cancer:
Autoimmune
Diseases:
Successful post Phase I/II trials for psoriasis,
site-directed formulation (IBD); topical formulation
(controlled-release) and oral formulation (psoriasis):
|
|
|
|
